

Stanford Cancer Institute

Cancer Cell Therapy

CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

CAR Therapies Following
Prior CAR Therapy

Expanded Access Protocols for
Commercial CAR-T Products
Manufactured of Specification

3rd Line CAR Therapies

Age < 65 Years

Age > 65 Years

[CCT5029](#)
Phase I/Ib
Autologous
CD22 CAR T
Cells in
Adults w/
Recurrent or
Refractory B
Cell
Malignancies

PI: Muffy
Sponsor:
Stanford
University

[CCT5051](#)
Phase I
ADI-001
Anti-CD20
CAR-
Engineered
Allogeneic
Gamma
Delta T Cells
+/-IL-2 in
BCell
Malignancies

PI: Miklos
Sponsor:
Adicet Bio,
Inc.

[CCT5016](#)
Managed
Access
Program
(MAP)
CTL019 in
ALL or
DLBCL

PI: Miklos
Sponsor:
Novartis

[CCT5044](#)
Phase I
Open-label,
Multicenter
KITE-363
(Autologous
Anti-CD19/
CD20 CAR
T-Cell
Therapy) in
Relapsed
and/or
Refractory
B-Cell
Lymphoma

PI: Dahiya
Sponsor:
Kite Pharma,
Inc.

Priority 1

[CCT5042](#)
Phase II
Anti-CD20
&Anti-CD19
Specific
Chimeric
Antigen
Receptor in
Relapsed
and/or
Refractory
DLBCL

PI: Miklos
Sponsor:
Miltenyi
Biomedicine,
GmbH

KEY

- Pending
- Open for Enrollment
- Observational Study
- Enrollment on Hold
- Optional Path
- Link Trial Posting
- Extension Study
- Immunotherapy